We are live on ! Find out more
NVCR icon

NovoCure
NVCR

104 hedge funds and large institutions have $746M invested in NovoCure in 2017 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 37 increasing their positions, 24 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

414% more call options, than puts

Call options by funds: $24.4M | Put options by funds: $4.75M

222% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 9

54% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 24

31% more capital invested

Capital invested by funds: $567M → $746M (+$178M)

22% more funds holding

Funds holding: 85 → 104 (+19)

5% more ownership

Funds ownership: 37.2% → 42.2% (+5%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
104
Holders Change
+19
Holders Change %
+22.35%
% of All Funds
2.59%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
29
Increased
37
Reduced
24
Closed
9
Calls
$24.4M
Puts
$4.75M
Net Calls
+$19.7M
Net Calls Change
+$3.68M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$17.9M
2
AC
Ascend Capital
California
+$12.9M
3
LCM
Laurion Capital Management
New York
+$10.9M
4
Norges Bank
Norges Bank
Norway
+$8.83M
5
CM
Castleark Management
Illinois
+$8.81M

Top Sellers

Rank Fund Capital Flow
1
RPAM
Rhenman & Partners Asset Management
Sweden
-$10.8M
2
HCM
Highline Capital Management
New York
-$4.36M
3
PCM
Peregrine Capital Management
Minnesota
-$4.3M
4
SG
StepStone Group
California
-$3.93M
5
TA
Tamarack Advisers
California
-$3.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
TF
76
TIAA FSB
Florida
$273K – – –
US Bancorp
77
US Bancorp
Minnesota
$258K +$59K +3,000 +30%
Nisa Investment Advisors
78
Nisa Investment Advisors
Missouri
$238K +$39.3K +2,000 +20%
AP
79
AHL Partners
United Kingdom
$231K +$229K +11,639 New
Barclays
80
Barclays
United Kingdom
$226K +$114K +5,787 +104%
TAM
81
Tyers Asset Management
Texas
$221K – – –
TI
82
Trexquant Investment
Connecticut
$212K +$210K +10,690 New
TRCT
83
Tower Research Capital (TRC)
New York
$199K +$124K +6,300 +170%
PCM
84
Prelude Capital Management
New York
$188K +$186K +9,461 New
RCM
85
Riverhead Capital Management
Delaware
$180K – – –
UBS Group
86
UBS Group
Switzerland
$161K -$9.79K -498 -6%
GHCM
87
Glen Harbor Capital Management
California
$161K – – –
Royal Bank of Canada
88
Royal Bank of Canada
Ontario, Canada
$148K +$140K +7,112 +2,142%
Bank of Montreal
89
Bank of Montreal
Ontario, Canada
$140K – – –
BNP Paribas Financial Markets
90
BNP Paribas Financial Markets
France
$136K -$7.37K -375 -5%
AIP
91
Ameritas Investment Partners
Nebraska
$103K – – –
CG
92
Cutler Group
California
$88K +$88K +4,477 New
Simplex Trading
93
Simplex Trading
Illinois
$51K -$73.4K -3,733 -59%
LTFS
94
Ladenburg Thalmann Financial Services
Florida
$41K +$29.5K +1,500 +280%
FDCDDQ
95
Federation des caisses Desjardins du Quebec
Quebec, Canada
$39.5K – – –
BCM
96
Blume Capital Management
California
$20K – – –
FAM
97
Fred Alger Management
New York
$20K +$19.7K +1,000 New
Zurich Cantonal Bank
98
Zurich Cantonal Bank
Switzerland
$15K +$14.6K +744 New
Citigroup
99
Citigroup
New York
$12K +$688 +35 +6%
WAS
100
Winch Advisory Services
Wisconsin
$12K +$11.8K +600 New
1 2 3
4
5

NVCR Hedge Fund Activity: Q3 2017 in Review

104 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q3 2017, worth a combined $746M — up 31% from $567M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new NVCR positions and 9 closed out — a net gain of 20 holders — while 37 added to existing stakes and 24 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $17.9M. The largest seller was Rhenman & Partners Asset Management, cutting an estimated $10.8M.

  • 104 institutional investors held NovoCure (NVCR) as of Q3 2017, up from 85 in Q2 2017.
  • Funds reported $746M of NovoCure stock for Q3 2017, up 31% quarter-over-quarter.
  • 29 funds opened new NovoCure positions in Q3 2017 and 9 closed out, a net change of +20 holders.
  • The largest NovoCure buyer in Q3 2017 was Fidelity Investments, an estimated $17.9M added.
  • The largest NovoCure seller in Q3 2017 was Rhenman & Partners Asset Management, an estimated $10.8M sold.

Based on aggregated 13F filings for Q3 2017.